<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28676" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Ryanodine Receptor</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Raszewski</surname>
            <given-names>Jesse A.</given-names>
          </name>
          <aff>Alabama College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jesse Raszewski declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28676.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A ryanodine receptor is a homotetrameric channel with a molecular mass of more than 2.2 megadaltons.<xref ref-type="bibr" rid="article-28676.r1">[1]</xref>&#x000a0;It is the largest known ion channel and gets its name from one of its exogenous ligands, ryanodine, an alkaloid plant toxin from <italic toggle="yes">Ryania speciosa</italic>.<xref ref-type="bibr" rid="article-28676.r2">[2]</xref>&#x000a0;Ryanodine receptor ion channels are embedded in the internal side of the sarcoplasmic reticulum that stores calcium, which is fundamental to striated muscle.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;They are high-conductance, monovalent, or divalent conducting channels regulated by multiple factors, including calcium, magnesium, adenosine triphosphate, calmodulin, protein kinases and phosphatases, and redox-active species.<xref ref-type="bibr" rid="article-28676.r4">[4]</xref>&#x000a0;Ryanodine receptors are essential for excitation-contraction coupling, linking action potentials and contraction of the striated muscle by releasing calcium ions required to activate the contractile proteins.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;These proteins are studied to develop therapeutic advances in diseases associated with striated muscle.</p>
      </sec>
      <sec id="article-28676.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>One issue of concern when studying these proteins is their size. Ryanodine receptors are the largest known ion channels capable of creating a rapid and transient increase in the cytosolic calcium levels within the cell.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;The analysis of the primary structure of these proteins demonstrates many functional motifs that are present in other proteins. Still, the role of ryanodine receptors has not been fully elucidated due to the size of the gene.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;The massive size of the gene, the multitude of modulators, and the dynamic nature of the channel make the structural analysis very difficult.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;The many advances in electron microscopy are beginning&#x000a0;to decode many vital receptor features.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref></p>
      </sec>
      <sec id="article-28676.s3" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>A ryanodine receptor comprises&#x000a0;4 polypeptides, each consisting of around 5000 amino acids, and four FK506-binding proteins, each consisting of approximately 110 amino acids.<xref ref-type="bibr" rid="article-28676.r4">[4]</xref>&#x000a0;Moreover, the type 1 ryanodine receptor is the major isoform expressed in skeletal muscle, and the type 2 ryanodine receptor is the major isoform expressed in cardiac muscle.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;</p>
        <p>In skeletal muscle, calcium release units arrange themselves in triads composed of three elements:&#x000a0;2 terminal expansions of the sarcoplasmic reticulum on either side that form a junction with the third component, the t-tubule.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;Within these junctions, the ryanodine receptors form a double row of channels that form "couplons" with the dihydropyridine receptors in the t-tubule membrane.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;The t-tubules enter the muscle fibers via caveolae, and these align with the A. I band and overlap on either side of the Z-line within the sarcomere, which forms a double band in each sarcomere that repeats at spaced intervals along the length of a muscle fiber.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref></p>
        <p>In cardiac muscle, calcium release units arrange themselves in dyads, containing only&#x000a0;2 elements: a single terminal sarcoplasmic reticulum expansion forming a junction with the surface of the t-tubule membrane.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;The cardiac sarcoplasmic reticulum expansions are relatively narrow, and these dyads align with the Z-line, forming a single band in each cardiac muscle sarcomere.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref></p>
      </sec>
      <sec id="article-28676.s4" sec-type="Development">
        <title>Development</title>
        <p>The functional ryanodine receptor ion channel is formed by&#x000a0;4 monomers, each with more than 5000 residues, constituting the largest ion channel protein identified so far.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;In humans, the gene that encodes the type 1 ryanodine receptor channel protein that commonly presents in skeletal muscle has its location on chromosome 19q13.2 and spans 104 exons.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;The gene encodes the type 2 ryanodine receptor in cardiac muscle on chromosome 1q43 and spans 102 exons.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;The type 3 ryanodine receptor gene is located in chromosome 15q13.3-14 and spans 103 exons.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-28676.s5" sec-type="Organ Systems Involved">
        <title>Organ Systems Involved</title>
        <p>There are&#x000a0;3 different isoforms of ryanodine receptors found in mammals.<xref ref-type="bibr" rid="article-28676.r2">[2]</xref>&#x000a0;They share around 65% of the gene sequence identity and have subtle functional differences.<xref ref-type="bibr" rid="article-28676.r2">[2]</xref></p>
        <p>The type 1 ryanodine receptor is primarily found in skeletal muscles and is at the junctional region of the terminal sarcoplasmic reticulum.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;The type 1 channel may also express very low levels in cardiac muscle, smooth muscle, stomach, kidney, thymus, cerebellum, Purkinje cells, adrenal glands, ovaries, and the testes.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref> New studies have shown that type 1 receptors may even be expressed in B-lymphocytes.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;The predominant form of the ryanodine receptor in cardiac muscle is the type 2 receptor.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;The type 2 ryanodine receptor also expresses at high levels in the Purkinje cells of the cerebellum and cerebral cortex and low levels in the stomach, kidneys, adrenal glands, ovaries, thymus, and lungs.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;The type 3 ryanodine receptors get expressed in the hippocampal neurons, thalamus, Purkinje cells, corpus striatum, and in the skeletal muscles predominantly located in the diaphragm, the smooth muscle cells of the coronary vasculature, lungs, kidneys, ileum, jejunum, spleen, stomach, aorta, uterus, ureters, urinary bladder, and esophagus.<xref ref-type="bibr" rid="article-28676.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-28676.s6" sec-type="Function">
        <title>Function</title>
        <p>The ryanodine receptor is a conduit for calcium to flow through and produce contractions in striated muscles.</p>
        <p>In skeletal muscle, the depolarization from the action potential leads to a protein-to-protein interaction across the junctional cleft between the dihydropyridine receptor and the ryanodine receptor type 1 to release calcium from the sarcoplasmic reticulum to produce a muscle contraction.<xref ref-type="bibr" rid="article-28676.r6">[6]</xref></p>
        <p>In cardiac muscle during systole, calcium is released from the sarcoplasmic reticulum by directly activating the type 2 ryanodine receptors by an inward current of calcium via the L-type calcium channels during excitation produced from the action potential.<xref ref-type="bibr" rid="article-28676.r7">[7]</xref>&#x000a0;This calcium-induced calcium release occurs at specialized microdomains where the sarcolemma T- tubule closely approaches the sarcoplasmic reticulum's junction, forming the dyad structure.<xref ref-type="bibr" rid="article-28676.r7">[7]</xref>&#x000a0;The spatiotemporal&#x000a0;summation of this calcium-induced&#x000a0;calcium release generates contraction within the cardiac muscle.<xref ref-type="bibr" rid="article-28676.r7">[7]</xref></p>
      </sec>
      <sec id="article-28676.s7" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>Historically, it has been shown that&#x000a0;3 properties are essential for muscle contraction: sensitivity level to ryanodine, the rapidity of calcium release from the sarcoplasmic reticulum, and the ryanodine receptor.<xref ref-type="bibr" rid="article-28676.r2">[2]</xref>&#x000a0;The ryanodine receptors are calcium-gated cationic ion channels weakly selective for calcium over other cations.<xref ref-type="bibr" rid="article-28676.r2">[2]</xref>&#x000a0;The mechanism via which the channel activates is excitation-coupling and is tissue-specific. Excitation-contraction coupling encompasses the many complex processes linking surface membrane action potentials to the shortening of the muscle fiber, which has evolved over the years to incorporate only the mechanism linking the depolarization-dependent response of the dihydropyridine receptor voltage sensor with the release of the calcium from the sarcoplasmic reticulum by the ryanodine receptors.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;</p>
        <p>The skeletal muscle excitation-contraction coupling appears to depend on the conformational change denoted through the protein-to-protein interactions that link dihydropyridine subunits to the type 1 ryanodine receptors.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;The voltage sensor response to the depolarization is measured as a "charge movement" across the surface and the t-tubule membrane.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref></p>
        <p>In cardiac excitation-contraction coupling, calcium ions enter the dyadic junction through the dihydropyridine receptor and activate the type 2 ryanodine receptors via calcium-induced calcium release.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;The dihydropyridine calcium influx is sufficient to activate several type 2 ryanodine receptors, and there is only one dihydropyridine receptor for every 4 to 10 type 2 receptor tetramer.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref>&#x000a0;This cardiac mechanism is dependent upon the extracellular level of calcium.<xref ref-type="bibr" rid="article-28676.r3">[3]</xref></p>
      </sec>
      <sec id="article-28676.s8" sec-type="Related Testing">
        <title>Related Testing</title>
        <p>One area of testing that has proven beneficial has been the use of fluorescence resonance energy transfer.<xref ref-type="bibr" rid="article-28676.r8">[8]</xref>&#x000a0;This method allows the user to discover compounds that modulate an intracellular calcium concentration of the ryanodine receptor.<xref ref-type="bibr" rid="article-28676.r8">[8]</xref>&#x000a0;The N-terminus intersubunit of the ryanodine receptor self-associates and has recently emerged as a critical structure-function parameter in regulating the channel.<xref ref-type="bibr" rid="article-28676.r9">[9]</xref>&#x000a0;Empirical evidence from a combination of testing has indicated that type 2 ryanodine receptor N-terminus, also conserved in type 1 and type 3 ryanodine receptors, is intricately involved in the canal's closure.<xref ref-type="bibr" rid="article-28676.r9">[9]</xref> These methods of testing have helped develop therapeutic applications in medicine.<xref ref-type="bibr" rid="article-28676.r8">[8]</xref></p>
      </sec>
      <sec id="article-28676.s9" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Mutations in ryanodine receptors primarily correlate with a range of myopathies and cardiac arrhythmia disorders. The Human Gene Mutation Database contains 563 mutations in the type 1 ryanodine receptors and 287 mutations in the type 2 ryanodine receptors known to cause inherited disease.<xref ref-type="bibr" rid="article-28676.r2">[2]</xref></p>
        <p>For example, in malignant hyperthermia, findings indicate that disruption of the N-terminus and central domain interaction within the ryanodine receptor becomes disrupted, leading to increased channel activity.<xref ref-type="bibr" rid="article-28676.r9">[9]</xref>&#x000a0;In catecholaminergic polymorphic ventricular tachycardia, findings indicate that a single amino acid substitution in the ryanodine receptor gene leads to the N-terminus and central domain unzipping that underlies the channel dysfunction and diastolic sarcoplasmic reticulum calcium leak.<xref ref-type="bibr" rid="article-28676.r9">[9]</xref></p>
      </sec>
      <sec id="article-28676.s10" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>More than 100 type-1 ryanodine receptor channel mutations are potentially present in skeletal muscle, including malignant hyperthermia, central core disease, and multi/minicore&#x000a0;disease.<xref ref-type="bibr" rid="article-28676.r4">[4]</xref> As for type 2 ryanodine receptors, more than 150 mutations lead to inherited pathology, including catecholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia type 2, and idiopathic ventricular fibrillation.<xref ref-type="bibr" rid="article-28676.r4">[4]</xref></p>
        <p>Malignant hyperthermia is a hypermetabolic syndrome that appears in susceptible patients after exposure to specific pharmacologic agents that induce abnormal regulation of the ryanodine receptors, producing a massive calcium release from the sarcoplasmic reticulum in striated muscle.<xref ref-type="bibr" rid="article-28676.r10">[10]</xref>&#x000a0;The symptoms include high fever, tachycardia, and muscle rigidity. Laboratory workup will show high CK and high potassium levels. It most commonly results from using volatile anesthetic agents (sevoflurane, halothane, isoflurane, and enflurane) and rarely by succinylcholine. Inheritance to the susceptibility is often autosomal dominant. Very infrequently, the disease may occur as a new mutation.&#x000a0;Dantrolene sodium is the therapy used to counteract malignant hyperthermia because it inhibits calcium release from the sarcoplasmic reticulum by antagonizing the type 1 ryanodine receptors.<xref ref-type="bibr" rid="article-28676.r10">[10]</xref></p>
        <p>Catecholaminergic polymorphic ventricular tachycardia is characterized by a polymorphic ventricular tachycardia in a high adrenergic tone, as in exercise.<xref ref-type="bibr" rid="article-28676.r11">[11]</xref> The mainstay of therapy is to avoid strenuous activity, and the first-line pharmacological treatment is beta-blockers to control the heart rate.<xref ref-type="bibr" rid="article-28676.r11">[11]</xref></p>
      </sec>
      <sec id="article-28676.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28676&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28676">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28676/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28676">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28676.s12">
        <title>References</title>
        <ref id="article-28676.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Efremov</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Leitner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aebersold</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raunser</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Architecture and conformational switch mechanism of the ryanodine receptor.</article-title>
            <source>Nature</source>
            <year>2015</year>
            <month>Jan</month>
            <day>01</day>
            <volume>517</volume>
            <issue>7532</issue>
            <fpage>39</fpage>
            <page-range>39-43</page-range>
            <pub-id pub-id-type="pmid">25470059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28676.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willegems</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Efremov</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Structural Details of the Ryanodine Receptor Calcium Release Channel and Its Gating Mechanism.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2017</year>
            <volume>981</volume>
            <fpage>179</fpage>
            <page-range>179-204</page-range>
            <pub-id pub-id-type="pmid">29594862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28676.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dulhunty</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Board</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Beard</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Casarotto</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Physiology and Pharmacology of Ryanodine Receptor Calcium Release Channels.</article-title>
            <source>Adv Pharmacol</source>
            <year>2017</year>
            <volume>79</volume>
            <fpage>287</fpage>
            <page-range>287-324</page-range>
            <pub-id pub-id-type="pmid">28528672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28676.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meissner</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The structural basis of ryanodine receptor ion channel function.</article-title>
            <source>J Gen Physiol</source>
            <year>2017</year>
            <month>Dec</month>
            <day>04</day>
            <volume>149</volume>
            <issue>12</issue>
            <fpage>1065</fpage>
            <page-range>1065-1089</page-range>
            <pub-id pub-id-type="pmid">29122978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28676.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanner</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Georgiou</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Ryanodine receptors: structure, expression, molecular details, and function in calcium release.</article-title>
            <source>Cold Spring Harb Perspect Biol</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>2</volume>
            <issue>11</issue>
            <fpage>a003996</fpage>
            <pub-id pub-id-type="pmid">20961976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28676.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santulli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Physiology and pathophysiology of excitation-contraction coupling: the functional role of ryanodine receptor.</article-title>
            <source>J Muscle Res Cell Motil</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-45</page-range>
            <pub-id pub-id-type="pmid">28653141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28676.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nikolaienko</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bovo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zima</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Redox Dependent Modifications of Ryanodine Receptor: Basic Mechanisms and Implications in Heart Diseases.</article-title>
            <source>Front Physiol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>1775</fpage>
            <pub-id pub-id-type="pmid">30574097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28676.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rebbeck</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Essawy</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Nitu</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Gillispie</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Bers</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Cornea</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>High-Throughput Screens to Discover Small-Molecule Modulators of Ryanodine Receptor Calcium Release Channels.</article-title>
            <source>SLAS Discov</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-186</page-range>
            <pub-id pub-id-type="pmid">27760856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28676.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seidel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Zissimopoulos</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Structural and functional interactions within ryanodine receptor.</article-title>
            <source>Biochem Soc Trans</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>377</fpage>
            <page-range>377-83</page-range>
            <pub-id pub-id-type="pmid">26009179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28676.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kollmann-Camaiora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alsina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dom&#x000ed;nguez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Del Blanco</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yepes</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Guerrero</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical protocol for the management of malignant hyperthermia.</article-title>
            <source>Rev Esp Anestesiol Reanim</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-40</page-range>
            <pub-id pub-id-type="pmid">27633384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28676.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieve</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>van der Werf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wilde</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Catecholaminergic Polymorphic Ventricular Tachycardia.</article-title>
            <source>Circ J</source>
            <year>2016</year>
            <month>May</month>
            <day>25</day>
            <volume>80</volume>
            <issue>6</issue>
            <fpage>1285</fpage>
            <page-range>1285-91</page-range>
            <pub-id pub-id-type="pmid">27180891</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
